secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scienture Holdings, Inc. (SCNX)
CIK:        0001382574
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001493152-25-009737
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scienture gets exclusive US rights to commercialize REZENOPY naloxone nasal spray from Kindeva
--------------------------------------------------------------------------------

- Exclusive 10-year US license to commercialize REZENOPY (naloxone HCl 10mg) from Kindeva; term expires 10 yrs from first commercial sale.
- Supply price $9.20/unit; profit-sharing 10% of net sales (8% upon generic entry); additional 5% until $12.8M NDA cost recovered.
- Milestone payments up to $10M based on net sales targets; $1M upfront milestones due in stages.
- Minimum order: 3 batches of 450,000 units/year from 2027 or $1.242M/year; $189M total naloxone market (IQVIA MAT Dec 2024).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382574/000149315225009737/0001493152-25-009737-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382574/000149315225009737/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-009737

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer